The OptiMARK clinical development program: Summary of safety data

Journal of Magnetic Resonance Imaging

Volumn 15, Issue 4, 2002, Pages 446-455

  Brown, Jeffrey J ^a   Kristy, Rita M ^a   Stevens, Gary R ^a   Pierro, Joseph A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Contrast agents; Gadolinium; MRI; Safety profile

Indexed keywords

GADOLINIUM PENTETATE; GADOVERSETAMIDE;

ABDOMINAL PAIN; ARTICLE; ASTHENIA; BACKACHE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DYSPEPSIA; ECCHYMOSIS; HEADACHE; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PRIORITY JOURNAL; RASH; RHINITIS; TASTE DISORDER; VASODILATATION; VERTIGO;

ADULT; CONTRAST MEDIA; DRUG TOLERANCE; FEMALE; GADOLINIUM DTPA; HUMANS; KIDNEY DISEASES; LIVER DISEASES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; SAFETY;

EID: 0036194140     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.10091     Document Type: Article

References (13)

1. Safety of magnetic resonance imaging contrast agents
2. Safety assessment of gadopentetate dimeglumine in U.S. clinical trials
3. Gadodiamide injection: Nonionic gadolinium chelate for MR imaging of the brain and spine - phase II-III clinical trial
4. Safety of gadoteridol injection: U.S. clinical trial experience
5. Clinical safety and efficacy of gadoteridol: A study in 411 patients with suspected intracranial and spinal disease
6. Worldwide clinical safety assessment of gadoteridol injection: An update
7. Multicenter evaluation of the safety, tolerance, and efficacy of OptiMARK in magnetic resonance imaging of the brain and spine
8. A multicenter, randomized double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with magnevist (gadopentetate dimeglumine) in patients with liver pathology: Results of a phase III clinical trial
9. Safety and efficacy of contrast-enhanced MRI in brain, head and neck: Gadodiamide injection versus gadopentetate dimeglumine
10. Contrast-enhanced MRI of the central nervous system: Comparison between gadodiamide injection and gadolinium-DTPA
11. Pharmacokinetics of gadodiamide injection in patients with moderately impaired renal function
12. Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function
13. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis